Stock Price Forecast

July 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sierra Oncology Inc chart...

About the Company

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

CEO

Stephen Dilly

Exchange

NASDAQ

Website

www.sierraoncology.com

$0M

Total Revenue

69

Employees

$1B

Market Capitalization

-8.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SRRA News

Sierra Oncology Inc. (SRRA)

1mon ago, source: Insider Monkey

Investor Bill Ackman said the new omicron variant of the coronavirus could actually give U.S. stocks a boost if symptoms turn out to be less severe. The latest 13F reporting period has come and ...

Sierra Oncology (NASDAQ: SRRA)

3y ago, source: The Motley Fool

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to ...

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

2y ago, source: pharmaphorum

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.

MSU vaccine-tech spinoff hopes it can make lightning strike again

9d ago, source: crainsgrandrapids

Don Parfet is hoping he can experience some deja vu all over again, to use a phrase coined by that great microbiologist Yogi ...

Patrick G Enright's Net Worth

2d ago, source: Benzinga.com

Who is Patrick G Enright? Patrick G Enright has an estimated net worth of $1.94 Billion. This is based on reported shares across multiple companies, which include VALENTIS INC, Inozyme Pharma, Inc ...

Champions Oncology, Inc. (CSBR)

7d ago, source: Yahoo Finance

HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions ...

IKNA Ikena Oncology, Inc.

2d ago, source: Seeking Alpha

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the ...

Oncology Pharma Inc ONPH

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRDF Cardiff Oncology, Inc.

10d ago, source: Seeking Alpha

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like ...

Champions Oncology, Inc.

1y ago, source: CNN

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...